Current campus guidelines for any gathering other than academic classes, professional education programs (GTPE), or department meetings are available at

Thursday, October 22 2020
11:00am - 12:00pm
Virtual Location | Registration Required
Add To My Calendar
NanoFANS Fall 2020 Series Session 4 | The ResonanceDx Bulk Acoustic Resonance Sensing Platform

The ResonanceDx Bulk Acoustic Resonance Sensing Platform

Carlos S. Moreno, Ph.D. | Associate Professor; Dept. of Pathology and Laboratory Medicine, Emory University School of Medicine

Abstract: As the global coronavirus pandemic continues, there is an urgent clinical and epidemiological need to be able to assess whether or not someone has contracted COVID19. The ResonanceDx Bulk Acoustic Resonance Sensing (BARS) platform detects the shifts in the piezoelectric acoustic resonant frequencies that occur upon antibody-antigen binding and is approximately an order of magnitude more sensitive than standard ELISA detection methods. Moreover, this approach provides results in approximately 5 minutes with no sample processing or expensive or hard to manufacture reagents, enabling the use of whole blood or saliva. The applications for such a rapid point-of-care COVID19 diagnostic test are numerous, including identifying exposed healthcare workers, safely facilitating regular procedures from dental visits to elective surgery, allowing family members to visit hospitals or nursing homes, allowing non-essential workers to return to work, college students to campus, safe travel on airlines or cruises, or admission to large gatherings for members of the general public.

Bio: Dr. Moreno obtained his B.S. and M.S. in Aeronautics and Astronautics from MIT, and worked for NASA before he earned his PhD in Genetics and Molecular Biology from Emory University in 1998. He is Associate Professor of Pathology & Laboratory Medicine and Biomedical Informatics at Emory University, where he is a member of the Winship Cancer Institute. He specializes in cancer bioinformatics and cancer genomics, and his laboratory has used whole genome expression analysis and next-generation sequencing to identify biomarkers of aggressive disease in prostate cancer. He is Section Editor-in-Chief of the Cancer Biomarkers section of the journal Cancers. He is a co-inventor on a patent application for a system to detect biomarkers using piezoelectric resonators. In 2017, he co-founded ResonanceDx to develop rapid, point-of-care diagnostic devices.

Register to receive meeting URL: